Literature DB >> 36008700

CircSOD2 Contributes to Tumor Progression, Immune Evasion and Anti-PD-1 Resistance in Hepatocellular Carcinoma by Targeting miR-497-5p/ANXA11 Axis.

Rong Ye1, Xingyu Lu2, Jianping Liu1, Qing Duan1, Junqi Xiao1, Xunhong Duan1, Zhibiao Yue3, Fengen Liu4.   

Abstract

Circular RNAs (circRNAs) can function as functional molecules in hepatocellular carcinoma (HCC). Herein, circRNA superoxide dismutase 2 (circSOD2) was researched in HCC progression and immune system. The real-time polymerase chain reaction (qRT-PCR) was used for quantification of circSOD2, microRNA-497-5p (miR-497-5p) and Annexin A11 (ANXA11). Cell assays were performed by 3-(4, 5-dimethylthiazol-2-y1)-2, 5-diphenyl tetrazolium bromide (MTT) and colony formation assays for proliferation, flow cytometry for apoptosis and cell cycle, wound healing assay for migration and transwell assay for migration/invasion. ANXA11 and metastatic protein levels were measured by western blot. Dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were performed to analyze target binding. CD8+ T cell immunity was assessed by Immunohistochemistry (IHC) assay, and the effect of circSOD2 on programmed cell death 1 (PD-1) immune checkpoint inhibitors (anti-PD-1) therapy was evaluated by mice xenograft assay. CircSOD2 was upregulated in HCC tissues and cells. Knockdown of circSOD2 resulted in HCC cell growth inhibition, apoptosis promotion, cell cycle arrest and metastasis suppression. Mechanically, circSOD2 promoted HCC development by acting as a miR-497-5p sponge and miR-497-5p played a tumor-inhibitory role in HCC cells by targeting ANXA11. Moreover, circSOD2 induced upregulation of ANXA11 expression by interacting with miR-497-5p. Also, the promoting effects of circSOD2 on immune evasion and anti-PD-1 resistance were related to miR-497-5p/ANXA11 axis. This study elucidated the pivotal function of circSOD2 in HCC progression and immunosuppression by mediating miR-497-6p/ANXA11 axis. CircSOD2/miR-497-5p/ANXA11 axis was a novel view of circRNA research in HCC.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ANXA11; CircSOD2; Hepatocellular carcinoma; Immune system; miR-497-5p

Year:  2022        PMID: 36008700     DOI: 10.1007/s10528-022-10273-w

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   2.220


  7 in total

1.  Circular RNA circRNA_0000285 promotes cervical cancer development by regulating FUS.

Authors:  R-X Chen; H-L Liu; L-L Yang; F-H Kang; L-P Xin; L-R Huang; Q-F Guo; Y-L Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-10       Impact factor: 3.507

2.  CircRNA ZFR stimulates the proliferation of hepatocellular carcinoma through upregulating MAP2K1.

Authors:  B C Cedric; T D M Souraka; Y-L Feng; P Kisembo; J-C Tu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-10       Impact factor: 3.507

3.  The circular RNA circPTK2 inhibits EMT in hepatocellular carcinoma by acting as a ceRNA and sponging miR-92a to upregulate E-cadherin.

Authors:  T-T Gong; F-Z Sun; J -Y Chen; J-F Liu; Y Yan; D Li; B Zhou; H Shan
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-09       Impact factor: 3.507

4.  Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis.

Authors:  Honglei Wang; Yi Xiao; Li Wu; Dachang Ma
Journal:  Int J Oncol       Date:  2018-02-05       Impact factor: 5.650

5.  MiR-497-5p inhibits cell proliferation and metastasis in hepatocellular carcinoma by targeting insulin-like growth factor 1.

Authors:  Guo-Shu Xu; Zi-Wei Li; Zhi-Ping Huang; F Charles Brunicardi; Fu Jia; Chao Song; Hai-Jian Zou; Rui-Fen Sun
Journal:  Mol Genet Genomic Med       Date:  2019-08-23       Impact factor: 2.183

6.  The Regulation of circRNA RNF13/miRNA-1224-5p Axis Promotes the Malignant Evolution in Acute Myeloid Leukemia.

Authors:  Rong Zhang; Yingchun Li; Hongtao Wang; Ke Zhu; Guojun Zhang
Journal:  Biomed Res Int       Date:  2020-10-06       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.